<?xml version="1.0" encoding="utf-8"?>
<oembed>
  <version>1</version>
  <type>rich</type>
  <provider_name>Libsyn</provider_name>
  <provider_url>https://www.libsyn.com</provider_url>
  <height>90</height>
  <width>600</width>
  <title>352. Chris Kiple, CEO of Solius Labs</title>
  <description>Today, I'm joined by Chris Kiple, CEO of Solius Labs. &amp;amp;nbsp; A decade in development, Solius’s FDA-cleared UVB light therapy device personalizes dosage by skin type, aiming to replicate the benefits of sunlight while minimizing carcinogenic risk.&amp;amp;nbsp; &amp;amp;nbsp; In this episode, we discuss sunlight as a foundational pillar of health and longevity.&amp;amp;nbsp; &amp;amp;nbsp; We also cover:  Why sun avoidance is deadlier than smoking Designing a skin scanner for personalized UVB dosing Moving UVB therapy from clinical dermatology to consumer health    Subscribe to the podcast → insider.fitt.co/podcast&amp;amp;nbsp; Subscribe to our newsletter → insider.fitt.co/subscribe&amp;amp;nbsp; Follow us on LinkedIn → linkedin.com/company/fittinsider&amp;amp;nbsp; &amp;amp;nbsp; Website: www.solius.com&amp;amp;nbsp; Instagram: https://www.instagram.com/soliuslabs&amp;amp;nbsp; &amp;amp;nbsp; - &amp;amp;nbsp; The Fitt Insider Podcast is brought to you by EGYM. Visit EGYM.com&amp;amp;nbsp; to learn more about its smart fitness ecosystem for fitness and health facilities. &amp;amp;nbsp; Fitt Talent: https://talent.fitt.co/&amp;amp;nbsp; Consulting: https://consulting.fitt.co/&amp;amp;nbsp; Investments: https://capital.fitt.co/&amp;amp;nbsp; &amp;amp;nbsp; Chapters: (00:00) Introduction (00:29) Swedish longevity study (01:20) Chris background and Solius overview (02:05) UVB light therapy foundation (04:00) 10-year development and timing (05:07) Sun exposure evolution and skin type (08:10) Solius technology and personalized dosing (09:35) Skin scanning and dosing mechanism (11:00) FDA clearance and safety focus (12:40) OTC vs. prescription positioning (14:15) Safety risk contextualization (15:42) Healthcare partnerships strategy (17:50) Dermatology focus (19:00) Orthopedic and cardiovascular applications (20:32) Longevity clinic partnerships (22:35) Swedish and UK biobank studies (26:00) Hormone production benefits (27:20) Cardiovascular and nitric oxide improvements (28:30) Microbiome diversity impact (31:15) Platform evolution and future devices (33:20) Team-building and advisory board (34:45) Listening to early users (36:40) Where to find (38:07) Conclusion </description>
  <author_name>Fitt Insider</author_name>
  <author_url>https://insider.fitt.co</author_url>
  <html>&lt;iframe title="Libsyn Player" style="border: none" src="//html5-player.libsyn.com/embed/episode/id/42444110/height/90/theme/custom/thumbnail/yes/direction/forward/render-playlist/no/custom-color/88AA3C/" height="90" width="600" scrolling="no"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen&gt;&lt;/iframe&gt;</html>
  <thumbnail_url>https://assets.libsyn.com/secure/content/205110200</thumbnail_url>
</oembed>
